KR100209180B1 - 아세만난을 포함하는 약제학적 조성물 - Google Patents

아세만난을 포함하는 약제학적 조성물 Download PDF

Info

Publication number: KR100209180B1
Authority: KR; South Korea
Prior art keywords: acemannan; cells; treatment; patients; cell
Prior art date: 1991-11-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

KR1019940701484A

Other languages

English (en)

Korean (ko)

Inventor

맥아날리 빌에이치

카펜터 로버트에이치

맥다니엘 하알리알

Original Assignee

터너 칼튼 이.

캐링턴 라보라토리즈인코포레이티드

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-11-05

Filing date

1991-11-05

Publication date

1999-07-15

1991-11-05 Application filed by 터너 칼튼 이., 캐링턴 라보라토리즈인코포레이티드 filed Critical 터너 칼튼 이.

1991-11-05 Priority claimed from PCT/US1991/008204 external-priority patent/WO1993008810A1/en

1999-07-15 Application granted granted Critical

1999-07-15 Publication of KR100209180B1 publication Critical patent/KR100209180B1/ko

2011-11-05 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

229960005327 acemannan Drugs 0.000 title claims abstract description 342
XOYXESIZZFUVRD-UVSAJTFZSA-M acemannan Chemical compound CC(=O)O[C@@H]1[C@H](O)[C@@H](OC)O[C@H](CO)[C@H]1O[C@@H]1[C@@H](O)[C@@H](OC(C)=O)[C@H](O[C@@H]2[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O[C@@H]4[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]5[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]6[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]7[C@H]([C@@H](OC(C)=O)[C@H](OC)[C@@H](CO)O7)O)[C@@H](CO)O6)O)[C@H](O5)C([O-])=O)O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](CO)O2)O)[C@@H](CO)O1 XOYXESIZZFUVRD-UVSAJTFZSA-M 0.000 title claims abstract 7
239000008194 pharmaceutical composition Substances 0.000 title claims description 7
210000004369 blood Anatomy 0.000 claims description 19
239000008280 blood Substances 0.000 claims description 19
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 16
239000002671 adjuvant Substances 0.000 claims description 9
231100000241 scar Toxicity 0.000 claims description 7
208000032544 Cicatrix Diseases 0.000 claims description 5
230000037387 scars Effects 0.000 claims description 5
230000032683 aging Effects 0.000 claims description 3
206010012601 diabetes mellitus Diseases 0.000 claims description 3
208000014085 Chronic respiratory disease Diseases 0.000 claims 1
210000004204 blood vessel Anatomy 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 105
241001465754 Metazoa Species 0.000 abstract description 68
206010028980 Neoplasm Diseases 0.000 abstract description 67
238000000034 method Methods 0.000 abstract description 48
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 38
201000010099 disease Diseases 0.000 abstract description 35
229920000057 Mannan Polymers 0.000 abstract description 33
208000015181 infectious disease Diseases 0.000 abstract description 29
241000196324 Embryophyta Species 0.000 abstract description 25
235000011399 aloe vera Nutrition 0.000 abstract description 21
210000000987 immune system Anatomy 0.000 abstract description 20
201000011510 cancer Diseases 0.000 abstract description 19
230000003612 virological effect Effects 0.000 abstract description 18
230000007246 mechanism Effects 0.000 abstract description 11
230000004936 stimulating effect Effects 0.000 abstract description 11
241001116389 Aloe Species 0.000 abstract description 9
206010061218 Inflammation Diseases 0.000 abstract description 5
230000004054 inflammatory process Effects 0.000 abstract description 5
230000002519 immonomodulatory effect Effects 0.000 abstract description 3
230000009545 invasion Effects 0.000 abstract 1
230000000241 respiratory effect Effects 0.000 abstract 1
XOYXESIZZFUVRD-YGGZJJQXSA-N (2S,3S,4R,5S,6R)-6-[(2R,3R,4R,5S,6S)-6-[(2R,3S,4S,5S,6S)-5-acetamido-6-[(2R,3R,4R,5S,6S)-4-acetyloxy-6-[(2R,3R,4R,5S,6S)-4-acetyloxy-6-[(2R,3R,4R,5S,6R)-4-acetyloxy-5-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxy-5-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-5-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-acetyloxy-5-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-acetyloxy-3-[(2S,3S,4R,5R,6R)-4-acetyloxy-5-[(2S,3S,4R,5R,6R)-4-acetyloxy-3-hydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxyoxane-2-carboxylic acid Chemical compound CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@H](CO)[C@@H](O[C@@H]4O[C@H](CO)[C@@H](O[C@@H]5O[C@H](CO)[C@@H](O[C@@H]6O[C@@H]([C@@H](O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](CO)[C@@H](OC)[C@H](OC(C)=O)[C@@H]8O)[C@H](OC(C)=O)[C@@H]7O)[C@H](OC(C)=O)[C@@H]6O)C(O)=O)[C@H](OC(C)=O)[C@@H]5O)[C@@H](O)[C@@H]4NC(C)=O)[C@H](OC(C)=O)[C@@H]3O)[C@H](OC(C)=O)[C@@H]2O)[C@H](OC(C)=O)[C@@H]1O XOYXESIZZFUVRD-YGGZJJQXSA-N 0.000 description 337
210000004027 cell Anatomy 0.000 description 161
230000000694 effects Effects 0.000 description 73
210000002540 macrophage Anatomy 0.000 description 54
208000024891 symptom Diseases 0.000 description 50
230000003902 lesion Effects 0.000 description 47
241000700605 Viruses Species 0.000 description 46
230000004044 response Effects 0.000 description 44
229920001282 polysaccharide Polymers 0.000 description 41
239000005017 polysaccharide Substances 0.000 description 41
150000004676 glycans Chemical class 0.000 description 40
238000002474 experimental method Methods 0.000 description 36
239000003814 drug Substances 0.000 description 35
210000004698 lymphocyte Anatomy 0.000 description 35
229940079593 drug Drugs 0.000 description 32
210000001616 monocyte Anatomy 0.000 description 32
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
210000001519 tissue Anatomy 0.000 description 31
230000001965 increasing effect Effects 0.000 description 30
239000011780 sodium chloride Substances 0.000 description 29
239000000427 antigen Substances 0.000 description 28
102000036639 antigens Human genes 0.000 description 28
108091007433 antigens Proteins 0.000 description 28
238000000338 in vitro Methods 0.000 description 28
239000000499 gel Substances 0.000 description 27
102000000589 Interleukin-1 Human genes 0.000 description 26
108010002352 Interleukin-1 Proteins 0.000 description 26
206010057249 Phagocytosis Diseases 0.000 description 24
230000002354 daily effect Effects 0.000 description 24
230000008782 phagocytosis Effects 0.000 description 24
238000012360 testing method Methods 0.000 description 24
108090000288 Glycoproteins Proteins 0.000 description 23
102000003886 Glycoproteins Human genes 0.000 description 23
208000031886 HIV Infections Diseases 0.000 description 23
239000000126 substance Substances 0.000 description 21
241000282414 Homo sapiens Species 0.000 description 20
239000000203 mixture Substances 0.000 description 20
229960005486 vaccine Drugs 0.000 description 20
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
241000713772 Human immunodeficiency virus 1 Species 0.000 description 18
210000001744 T-lymphocyte Anatomy 0.000 description 18
230000015572 biosynthetic process Effects 0.000 description 18
239000000839 emulsion Substances 0.000 description 18
238000002347 injection Methods 0.000 description 17
239000007924 injection Substances 0.000 description 17
239000000463 material Substances 0.000 description 17
239000000047 product Substances 0.000 description 17
241000283073 Equus caballus Species 0.000 description 16
241000282412 Homo Species 0.000 description 16
241000725303 Human immunodeficiency virus Species 0.000 description 16
230000000840 anti-viral effect Effects 0.000 description 16
230000002829 reductive effect Effects 0.000 description 16
210000002966 serum Anatomy 0.000 description 16
238000003786 synthesis reaction Methods 0.000 description 16
241000712079 Measles morbillivirus Species 0.000 description 15
241000699670 Mus sp. Species 0.000 description 15
238000004519 manufacturing process Methods 0.000 description 15
244000144927 Aloe barbadensis Species 0.000 description 14
235000002961 Aloe barbadensis Nutrition 0.000 description 14
230000000259 anti-tumor effect Effects 0.000 description 14
230000007423 decrease Effects 0.000 description 14
239000002609 medium Substances 0.000 description 14
210000003501 vero cell Anatomy 0.000 description 14
208000002193 Pain Diseases 0.000 description 13
150000001875 compounds Chemical class 0.000 description 13
238000011160 research Methods 0.000 description 13
239000000243 solution Substances 0.000 description 13
238000002560 therapeutic procedure Methods 0.000 description 13
208000022559 Inflammatory bowel disease Diseases 0.000 description 12
239000012980 RPMI-1640 medium Substances 0.000 description 12
206010012735 Diarrhoea Diseases 0.000 description 11
206010039491 Sarcoma Diseases 0.000 description 11
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
210000003743 erythrocyte Anatomy 0.000 description 11
239000002953 phosphate buffered saline Substances 0.000 description 11
210000000952 spleen Anatomy 0.000 description 11
238000002255 vaccination Methods 0.000 description 11
102000014150 Interferons Human genes 0.000 description 10
108010050904 Interferons Proteins 0.000 description 10
238000001574 biopsy Methods 0.000 description 10
230000008859 change Effects 0.000 description 10
238000002512 chemotherapy Methods 0.000 description 10
230000001419 dependent effect Effects 0.000 description 10
230000028993 immune response Effects 0.000 description 10
238000001727 in vivo Methods 0.000 description 10
238000001990 intravenous administration Methods 0.000 description 10
210000000265 leukocyte Anatomy 0.000 description 10
229920000642 polymer Polymers 0.000 description 10
230000001681 protective effect Effects 0.000 description 10
230000002195 synergetic effect Effects 0.000 description 10
230000001225 therapeutic effect Effects 0.000 description 10
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
208000025865 Ulcer Diseases 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
239000000284 extract Substances 0.000 description 9
230000001976 improved effect Effects 0.000 description 9
229940079322 interferon Drugs 0.000 description 9
210000004185 liver Anatomy 0.000 description 9
230000000394 mitotic effect Effects 0.000 description 9
210000005087 mononuclear cell Anatomy 0.000 description 9
201000006417 multiple sclerosis Diseases 0.000 description 9
230000003389 potentiating effect Effects 0.000 description 9
230000005855 radiation Effects 0.000 description 9
230000029812 viral genome replication Effects 0.000 description 9
241000282472 Canis lupus familiaris Species 0.000 description 8
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 8
150000001720 carbohydrates Chemical class 0.000 description 8
235000014633 carbohydrates Nutrition 0.000 description 8
235000005911 diet Nutrition 0.000 description 8
230000000408 embryogenic effect Effects 0.000 description 8
239000002158 endotoxin Substances 0.000 description 8
229960002949 fluorouracil Drugs 0.000 description 8
230000002458 infectious effect Effects 0.000 description 8
230000000242 pagocytic effect Effects 0.000 description 8
210000005259 peripheral blood Anatomy 0.000 description 8
239000011886 peripheral blood Substances 0.000 description 8
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 7
208000036142 Viral infection Diseases 0.000 description 7
208000027418 Wounds and injury Diseases 0.000 description 7
230000009471 action Effects 0.000 description 7
238000003556 assay Methods 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
230000001684 chronic effect Effects 0.000 description 7
230000037213 diet Effects 0.000 description 7
238000010790 dilution Methods 0.000 description 7
239000012895 dilution Substances 0.000 description 7
210000002950 fibroblast Anatomy 0.000 description 7
230000035876 healing Effects 0.000 description 7
230000006872 improvement Effects 0.000 description 7
238000011835 investigation Methods 0.000 description 7
210000001539 phagocyte Anatomy 0.000 description 7
206010039073 rheumatoid arthritis Diseases 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
230000009385 viral infection Effects 0.000 description 7
230000003442 weekly effect Effects 0.000 description 7
241000271566 Aves Species 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
229920001503 Glucan Polymers 0.000 description 6
206010020751 Hypersensitivity Diseases 0.000 description 6
241000124008 Mammalia Species 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
206010030113 Oedema Diseases 0.000 description 6
240000004808 Saccharomyces cerevisiae Species 0.000 description 6
230000001154 acute effect Effects 0.000 description 6
230000001464 adherent effect Effects 0.000 description 6
230000003013 cytotoxicity Effects 0.000 description 6
231100000135 cytotoxicity Toxicity 0.000 description 6
230000006378 damage Effects 0.000 description 6
231100000673 dose–response relationship Toxicity 0.000 description 6
239000012894 fetal calf serum Substances 0.000 description 6
229920006008 lipopolysaccharide Polymers 0.000 description 6
230000000144 pharmacologic effect Effects 0.000 description 6
239000012071 phase Substances 0.000 description 6
108010086652 phytohemagglutinin-P Proteins 0.000 description 6
230000008569 process Effects 0.000 description 6
238000010186 staining Methods 0.000 description 6
230000000638 stimulation Effects 0.000 description 6
208000011580 syndromic disease Diseases 0.000 description 6
210000001541 thymus gland Anatomy 0.000 description 6
231100000331 toxic Toxicity 0.000 description 6
230000002588 toxic effect Effects 0.000 description 6
231100000397 ulcer Toxicity 0.000 description 6
208000030507 AIDS Diseases 0.000 description 5
208000015943 Coeliac disease Diseases 0.000 description 5
241000283086 Equidae Species 0.000 description 5
108090000371 Esterases Proteins 0.000 description 5
239000012981 Hank's balanced salt solution Substances 0.000 description 5
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
230000004913 activation Effects 0.000 description 5
239000003242 anti bacterial agent Substances 0.000 description 5
229940088710 antibiotic agent Drugs 0.000 description 5
239000003443 antiviral agent Substances 0.000 description 5
239000002775 capsule Substances 0.000 description 5
230000003833 cell viability Effects 0.000 description 5
230000001472 cytotoxic effect Effects 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
238000001839 endoscopy Methods 0.000 description 5
230000012010 growth Effects 0.000 description 5
230000001506 immunosuppresive effect Effects 0.000 description 5
230000006698 induction Effects 0.000 description 5
230000002757 inflammatory effect Effects 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
208000014674 injury Diseases 0.000 description 5
239000007928 intraperitoneal injection Substances 0.000 description 5
244000045947 parasite Species 0.000 description 5
239000004033 plastic Substances 0.000 description 5
229920003023 plastic Polymers 0.000 description 5
230000009467 reduction Effects 0.000 description 5
210000004872 soft tissue Anatomy 0.000 description 5
239000002689 soil Substances 0.000 description 5
238000001356 surgical procedure Methods 0.000 description 5
229940071127 thioglycolate Drugs 0.000 description 5
CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 5
210000004881 tumor cell Anatomy 0.000 description 5
230000035899 viability Effects 0.000 description 5
229960004854 viral vaccine Drugs 0.000 description 5
230000029663 wound healing Effects 0.000 description 5
108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
235000001674 Agaricus brunnescens Nutrition 0.000 description 4
208000023275 Autoimmune disease Diseases 0.000 description 4
241000222122 Candida albicans Species 0.000 description 4
206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 4
208000011231 Crohn disease Diseases 0.000 description 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
229920000926 Galactomannan Polymers 0.000 description 4
229920002581 Glucomannan Polymers 0.000 description 4
208000037357 HIV infectious disease Diseases 0.000 description 4
101710154606 Hemagglutinin Proteins 0.000 description 4
102000001554 Hemoglobins Human genes 0.000 description 4
108010054147 Hemoglobins Proteins 0.000 description 4
206010062016 Immunosuppression Diseases 0.000 description 4
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
229930182816 L-glutamine Natural products 0.000 description 4
101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
102000007066 Prostate-Specific Antigen Human genes 0.000 description 4
108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
101710176177 Protein A56 Proteins 0.000 description 4
241000700159 Rattus Species 0.000 description 4
238000000692 Student's t-test Methods 0.000 description 4
206010052428 Wound Diseases 0.000 description 4
210000000683 abdominal cavity Anatomy 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
239000013566 allergen Substances 0.000 description 4
208000026935 allergic disease Diseases 0.000 description 4
230000003110 anti-inflammatory effect Effects 0.000 description 4
208000006673 asthma Diseases 0.000 description 4
239000012298 atmosphere Substances 0.000 description 4
210000000988 bone and bone Anatomy 0.000 description 4
210000001185 bone marrow Anatomy 0.000 description 4
206010006451 bronchitis Diseases 0.000 description 4
229940095731 candida albicans Drugs 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
230000003915 cell function Effects 0.000 description 4
239000006285 cell suspension Substances 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
235000012000 cholesterol Nutrition 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
231100000433 cytotoxic Toxicity 0.000 description 4
230000034994 death Effects 0.000 description 4
238000000502 dialysis Methods 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
235000019441 ethanol Nutrition 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
206010016256 fatigue Diseases 0.000 description 4
230000013595 glycosylation Effects 0.000 description 4
238000006206 glycosylation reaction Methods 0.000 description 4
210000003128 head Anatomy 0.000 description 4
239000000185 hemagglutinin Substances 0.000 description 4
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
230000003993 interaction Effects 0.000 description 4
238000007912 intraperitoneal administration Methods 0.000 description 4
238000010253 intravenous injection Methods 0.000 description 4
238000005259 measurement Methods 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
210000003716 mesoderm Anatomy 0.000 description 4
210000003205 muscle Anatomy 0.000 description 4
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 4
210000005036 nerve Anatomy 0.000 description 4
244000052769 pathogen Species 0.000 description 4
210000003024 peritoneal macrophage Anatomy 0.000 description 4
230000003285 pharmacodynamic effect Effects 0.000 description 4
239000000902 placebo Substances 0.000 description 4
229940068196 placebo Drugs 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
238000012545 processing Methods 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
230000010076 replication Effects 0.000 description 4
238000012552 review Methods 0.000 description 4
239000007787 solid Substances 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
235000000346 sugar Nutrition 0.000 description 4
229940104230 thymidine Drugs 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
239000003053 toxin Substances 0.000 description 4
231100000765 toxin Toxicity 0.000 description 4
108700012359 toxins Proteins 0.000 description 4
238000005406 washing Methods 0.000 description 4
LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 3
208000004998 Abdominal Pain Diseases 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
206010003445 Ascites Diseases 0.000 description 3
201000009030 Carcinoma Diseases 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
241000282326 Felis catus Species 0.000 description 3
201000008808 Fibrosarcoma Diseases 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
208000032843 Hemorrhage Diseases 0.000 description 3
108090001090 Lectins Proteins 0.000 description 3
102000004856 Lectins Human genes 0.000 description 3
102000009112 Mannose-Binding Lectin Human genes 0.000 description 3
108010087870 Mannose-Binding Lectin Proteins 0.000 description 3
206010028851 Necrosis Diseases 0.000 description 3
239000004677 Nylon Substances 0.000 description 3
208000000453 Skin Neoplasms Diseases 0.000 description 3
108020000999 Viral RNA Proteins 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000000556 agonist Substances 0.000 description 3
230000007815 allergy Effects 0.000 description 3
230000000735 allogeneic effect Effects 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000000935 antidepressant agent Substances 0.000 description 3
230000001363 autoimmune Effects 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
230000003115 biocidal effect Effects 0.000 description 3
208000034158 bleeding Diseases 0.000 description 3
230000000740 bleeding effect Effects 0.000 description 3
230000036765 blood level Effects 0.000 description 3
230000006037 cell lysis Effects 0.000 description 3
239000013553 cell monolayer Substances 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
238000009096 combination chemotherapy Methods 0.000 description 3
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
230000007123 defense Effects 0.000 description 3
239000000890 drug combination Substances 0.000 description 3
239000000975 dye Substances 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
210000003979 eosinophil Anatomy 0.000 description 3
210000000416 exudates and transudate Anatomy 0.000 description 3
235000013305 food Nutrition 0.000 description 3
239000012737 fresh medium Substances 0.000 description 3
230000006870 function Effects 0.000 description 3
229940046240 glucomannan Drugs 0.000 description 3
239000008103 glucose Substances 0.000 description 3
210000004209 hair Anatomy 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
238000001802 infusion Methods 0.000 description 3
230000018276 interleukin-1 production Effects 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
239000002523 lectin Substances 0.000 description 3
230000007774 longterm Effects 0.000 description 3
210000001165 lymph node Anatomy 0.000 description 3
230000001926 lymphatic effect Effects 0.000 description 3
LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 3
238000002156 mixing Methods 0.000 description 3
210000002433 mononuclear leukocyte Anatomy 0.000 description 3
210000003097 mucus Anatomy 0.000 description 3
230000017074 necrotic cell death Effects 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
229920001778 nylon Polymers 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
239000001814 pectin Substances 0.000 description 3
229920001277 pectin Polymers 0.000 description 3
235000010987 pectin Nutrition 0.000 description 3
201000000317 pneumocystosis Diseases 0.000 description 3
239000013641 positive control Substances 0.000 description 3
244000144977 poultry Species 0.000 description 3
235000013594 poultry meat Nutrition 0.000 description 3
239000000843 powder Substances 0.000 description 3
235000021251 pulses Nutrition 0.000 description 3
238000001959 radiotherapy Methods 0.000 description 3
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
238000002271 resection Methods 0.000 description 3
201000003068 rheumatic fever Diseases 0.000 description 3
238000004062 sedimentation Methods 0.000 description 3
206010040882 skin lesion Diseases 0.000 description 3
231100000444 skin lesion Toxicity 0.000 description 3
210000004989 spleen cell Anatomy 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
239000000758 substrate Substances 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
229940033663 thimerosal Drugs 0.000 description 3
239000001973 thioglycolate broth Substances 0.000 description 3
230000002992 thymic effect Effects 0.000 description 3
206010044652 trigeminal neuralgia Diseases 0.000 description 3
201000008827 tuberculosis Diseases 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
230000002792 vascular Effects 0.000 description 3
230000004580 weight loss Effects 0.000 description 3
OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
ATUBIBZJAGAIBW-WGEALTPQSA-N 4-[(2r,5s,6e,8z)-2-hydroxy-5,7-dimethyl-4-oxodeca-6,8-dienyl]piperidine-2,6-dione Chemical compound C\C=C/C(/C)=C/[C@H](C)C(=O)C[C@H](O)CC1CC(=O)NC(=O)C1 ATUBIBZJAGAIBW-WGEALTPQSA-N 0.000 description 2
ATUBIBZJAGAIBW-TXTWTNGRSA-N 9-methylstreptimidone Natural products CC=C/C(=C/C(C)C(=O)CC(O)CC1CC(=O)NC(=O)C1)/C ATUBIBZJAGAIBW-TXTWTNGRSA-N 0.000 description 2
240000007474 Aloe arborescens Species 0.000 description 2
235000004509 Aloe arborescens Nutrition 0.000 description 2
YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
238000011749 CBA mouse Methods 0.000 description 2
241000222120 Candida <Saccharomycetales> Species 0.000 description 2
206010009900 Colitis ulcerative Diseases 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
206010010741 Conjunctivitis Diseases 0.000 description 2
206010011502 Cryptosporidiosis infection Diseases 0.000 description 2
201000003883 Cystic fibrosis Diseases 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
206010017533 Fungal infection Diseases 0.000 description 2
208000003098 Ganglion Cysts Diseases 0.000 description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
229920002907 Guar gum Polymers 0.000 description 2
206010019695 Hepatic neoplasm Diseases 0.000 description 2
102100034349 Integrase Human genes 0.000 description 2
208000007766 Kaposi sarcoma Diseases 0.000 description 2
240000000599 Lentinula edodes Species 0.000 description 2
235000001715 Lentinula edodes Nutrition 0.000 description 2
102000008072 Lymphokines Human genes 0.000 description 2
108010074338 Lymphokines Proteins 0.000 description 2
206010025476 Malabsorption Diseases 0.000 description 2
208000004155 Malabsorption Syndromes Diseases 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
241001529936 Murinae Species 0.000 description 2
208000007101 Muscle Cramp Diseases 0.000 description 2
208000031888 Mycoses Diseases 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
206010028813 Nausea Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
241001494479 Pecora Species 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
208000012641 Pigmentation disease Diseases 0.000 description 2
208000037656 Respiratory Sounds Diseases 0.000 description 2
241000235070 Saccharomyces Species 0.000 description 2
206010040943 Skin Ulcer Diseases 0.000 description 2
206010067868 Skin mass Diseases 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
208000005392 Spasm Diseases 0.000 description 2
208000005400 Synovial Cyst Diseases 0.000 description 2
230000005867 T cell response Effects 0.000 description 2
201000006704 Ulcerative Colitis Diseases 0.000 description 2
206010047924 Wheezing Diseases 0.000 description 2
238000005299 abrasion Methods 0.000 description 2
206010000269 abscess Diseases 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
238000006640 acetylation reaction Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
208000009956 adenocarcinoma Diseases 0.000 description 2
238000009098 adjuvant therapy Methods 0.000 description 2
229940009456 adriamycin Drugs 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
229940035676 analgesics Drugs 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
150000004056 anthraquinones Chemical class 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
230000002924 anti-infective effect Effects 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
229960000074 biopharmaceutical Drugs 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000011748 cell maturation Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
208000019902 chronic diarrheal disease Diseases 0.000 description 2
231100001256 chronic oral toxicity Toxicity 0.000 description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
229960004316 cisplatin Drugs 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
230000001332 colony forming effect Effects 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
239000002537 cosmetic Substances 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
230000000378 dietary effect Effects 0.000 description 2
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
238000009826 distribution Methods 0.000 description 2
230000035622 drinking Effects 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
210000003981 ectoderm Anatomy 0.000 description 2
235000013601 eggs Nutrition 0.000 description 2
210000001900 endoderm Anatomy 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
239000003344 environmental pollutant Substances 0.000 description 2
AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
230000001815 facial effect Effects 0.000 description 2
239000000835 fiber Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
239000000417 fungicide Substances 0.000 description 2
229930182830 galactose Natural products 0.000 description 2
229960003082 galactose Drugs 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
229930182470 glycoside Natural products 0.000 description 2
210000000224 granular leucocyte Anatomy 0.000 description 2
239000000665 guar gum Substances 0.000 description 2
235000010417 guar gum Nutrition 0.000 description 2
229960002154 guar gum Drugs 0.000 description 2
230000035931 haemagglutination Effects 0.000 description 2
210000003958 hematopoietic stem cell Anatomy 0.000 description 2
230000002962 histologic effect Effects 0.000 description 2
238000010562 histological examination Methods 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
230000009610 hypersensitivity Effects 0.000 description 2
210000002865 immune cell Anatomy 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000016784 immunoglobulin production Effects 0.000 description 2
239000000367 immunologic factor Substances 0.000 description 2
239000002955 immunomodulating agent Substances 0.000 description 2
229940121354 immunomodulator Drugs 0.000 description 2
230000003308 immunostimulating effect Effects 0.000 description 2
239000000411 inducer Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
230000002601 intratumoral effect Effects 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
210000002414 leg Anatomy 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
206010025135 lupus erythematosus Diseases 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
244000005700 microbiome Species 0.000 description 2
239000003094 microcapsule Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000000178 monomer Substances 0.000 description 2
230000000877 morphologic effect Effects 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
230000003843 mucus production Effects 0.000 description 2
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
210000002850 nasal mucosa Anatomy 0.000 description 2
210000000822 natural killer cell Anatomy 0.000 description 2
230000008693 nausea Effects 0.000 description 2
239000013642 negative control Substances 0.000 description 2
230000001722 neurochemical effect Effects 0.000 description 2
231100000957 no side effect Toxicity 0.000 description 2
230000035764 nutrition Effects 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000007170 pathology Effects 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000019612 pigmentation Effects 0.000 description 2
231100000614 poison Toxicity 0.000 description 2
230000002980 postoperative effect Effects 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
229960004618 prednisone Drugs 0.000 description 2
108090000765 processed proteins & peptides Chemical group 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol hydrochloride Natural products C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000001698 pyrogenic effect Effects 0.000 description 2
239000000700 radioactive tracer Substances 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
206010039083 rhinitis Diseases 0.000 description 2
229960000885 rifabutin Drugs 0.000 description 2
ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 description 2
239000000523 sample Substances 0.000 description 2
238000005070 sampling Methods 0.000 description 2
201000000306 sarcoidosis Diseases 0.000 description 2
230000028327 secretion Effects 0.000 description 2
230000035939 shock Effects 0.000 description 2
239000002356 single layer Substances 0.000 description 2
235000020183 skimmed milk Nutrition 0.000 description 2
201000000849 skin cancer Diseases 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
230000019635 sulfation Effects 0.000 description 2
238000005670 sulfation reaction Methods 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 2
201000004647 tinea pedis Diseases 0.000 description 2
230000017423 tissue regeneration Effects 0.000 description 2
238000004448 titration Methods 0.000 description 2
210000003371 toe Anatomy 0.000 description 2
238000003325 tomography Methods 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000002110 toxicologic effect Effects 0.000 description 2
231100000041 toxicology testing Toxicity 0.000 description 2
210000003901 trigeminal nerve Anatomy 0.000 description 2
230000036269 ulceration Effects 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
239000011345 viscous material Substances 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 1
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 1
238000010600 3H thymidine incorporation assay Methods 0.000 description 1
LHYQAEFVHIZFLR-UHFFFAOYSA-L 4-(4-diazonio-3-methoxyphenyl)-2-methoxybenzenediazonium;dichloride Chemical compound [Cl-].[Cl-].C1=C([N+]#N)C(OC)=CC(C=2C=C(OC)C([N+]#N)=CC=2)=C1 LHYQAEFVHIZFLR-UHFFFAOYSA-L 0.000 description 1
206010000077 Abdominal mass Diseases 0.000 description 1
241000238876 Acari Species 0.000 description 1
208000010444 Acidosis Diseases 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
102000011767 Acute-Phase Proteins Human genes 0.000 description 1
108010062271 Acute-Phase Proteins Proteins 0.000 description 1
244000251953 Agaricus brunnescens Species 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
241001465677 Ancylostomatoidea Species 0.000 description 1
241000238421 Arthropoda Species 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
206010006448 Bronchiolitis Diseases 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
206010006811 Bursitis Diseases 0.000 description 1
210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
241000283707 Capra Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
108010051152 Carboxylesterase Proteins 0.000 description 1
102000013392 Carboxylesterase Human genes 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
244000132059 Carica parviflora Species 0.000 description 1
235000014653 Carica parviflora Nutrition 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
206010007882 Cellulitis Diseases 0.000 description 1
206010051290 Central nervous system lesion Diseases 0.000 description 1
206010008479 Chest Pain Diseases 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241000223205 Coccidioides immitis Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010010144 Completed suicide Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
208000023373 Crohn ileitis Diseases 0.000 description 1
208000008953 Cryptosporidiosis Diseases 0.000 description 1
244000301850 Cupressus sempervirens Species 0.000 description 1
244000303965 Cyamopsis psoralioides Species 0.000 description 1
241000235646 Cyberlindnera jadinii Species 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
206010011831 Cytomegalovirus infection Diseases 0.000 description 1
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
125000003423 D-mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
101710121417 Envelope glycoprotein Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
208000004729 Feline Leukemia Diseases 0.000 description 1
241000282324 Felis Species 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
229920000855 Fucoidan Polymers 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
108010068370 Glutens Proteins 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
108010031186 Glycoside Hydrolases Proteins 0.000 description 1
102000005744 Glycoside Hydrolases Human genes 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
240000001080 Grifola frondosa Species 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
229920002488 Hemicellulose Polymers 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101001040734 Homo sapiens Golgi phosphoprotein 3 Proteins 0.000 description 1
208000004454 Hyperalgesia Diseases 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
208000035154 Hyperesthesia Diseases 0.000 description 1
208000008454 Hyperhidrosis Diseases 0.000 description 1
206010020649 Hyperkeratosis Diseases 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010020843 Hyperthermia Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
208000001126 Keratosis Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
208000005230 Leg Ulcer Diseases 0.000 description 1
229920001491 Lentinan Polymers 0.000 description 1
241000222418 Lentinus Species 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
241000234280 Liliaceae Species 0.000 description 1
241001149691 Lipomyces starkeyi Species 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
208000032912 Local swelling Diseases 0.000 description 1
229920000161 Locust bean gum Polymers 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
208000007433 Lymphatic Metastasis Diseases 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
102000001696 Mannosidases Human genes 0.000 description 1
108010054377 Mannosidases Proteins 0.000 description 1
102100025315 Mannosyl-oligosaccharide glucosidase Human genes 0.000 description 1
102000006722 Mannosyltransferases Human genes 0.000 description 1
108010087568 Mannosyltransferases Proteins 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
206010027076 Mediastinal mass Diseases 0.000 description 1
206010027452 Metastases to bone Diseases 0.000 description 1
206010027457 Metastases to liver Diseases 0.000 description 1
206010028034 Mouth ulceration Diseases 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
241000186359 Mycobacterium Species 0.000 description 1
108010083674 Myelin Proteins Proteins 0.000 description 1
102000006386 Myelin Proteins Human genes 0.000 description 1
201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
206010059605 Necrobiosis Diseases 0.000 description 1
208000015906 Necrobiotic disease Diseases 0.000 description 1
206010029098 Neoplasm skin Diseases 0.000 description 1
206010029155 Nephropathy toxic Diseases 0.000 description 1
102000003729 Neprilysin Human genes 0.000 description 1
108090000028 Neprilysin Proteins 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
206010030154 Oesophageal candidiasis Diseases 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
208000007117 Oral Ulcer Diseases 0.000 description 1
206010068319 Oropharyngeal pain Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
235000014676 Phragmites communis Nutrition 0.000 description 1
108010089814 Plant Lectins Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
241000233870 Pneumocystis Species 0.000 description 1
206010035660 Pneumocystis Infections Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
208000008601 Polycythemia Diseases 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
208000004210 Pressure Ulcer Diseases 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
206010038019 Rectal adenocarcinoma Diseases 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
206010038997 Retroviral infections Diseases 0.000 description 1
102000002278 Ribosomal Proteins Human genes 0.000 description 1
108010000605 Ribosomal Proteins Proteins 0.000 description 1
229940124968 Rubella virus vaccine Drugs 0.000 description 1
241001453636 Salvinia Species 0.000 description 1
208000006268 Sarcoma 180 Diseases 0.000 description 1
208000008765 Sciatica Diseases 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
241000270295 Serpentes Species 0.000 description 1
102000005686 Serum Globulins Human genes 0.000 description 1
108010045362 Serum Globulins Proteins 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
208000004078 Snake Bites Diseases 0.000 description 1
208000021712 Soft tissue sarcoma Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
241000813920 Streptomyces pseudoechinosporeus Species 0.000 description 1
206010042496 Sunburn Diseases 0.000 description 1
208000002847 Surgical Wound Diseases 0.000 description 1
208000000491 Tendinopathy Diseases 0.000 description 1
206010043255 Tendonitis Diseases 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
206010053615 Thermal burn Diseases 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
206010047642 Vitiligo Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
AXIKDPDWFVPGOD-UHFFFAOYSA-O [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;2-(2,4,5,7-tetrabromo-3,6-dihydroxyxanthen-10-ium-9-yl)benzoic acid Chemical compound C1=CC(=[N+](C)C)C=C2SC3=CC(N(C)C)=CC=C3N=C21.OC(=O)C1=CC=CC=C1C1=C(C=C(Br)C(O)=C2Br)C2=[O+]C2=C1C=C(Br)C(O)=C2Br AXIKDPDWFVPGOD-UHFFFAOYSA-O 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000007950 acidosis Effects 0.000 description 1
208000026545 acidosis disease Diseases 0.000 description 1
206010000496 acne Diseases 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
210000003423 ankle Anatomy 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
230000001032 anti-candidal effect Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000001494 anti-thymocyte effect Effects 0.000 description 1
230000002365 anti-tubercular Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000013059 antihormonal agent Substances 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
210000003567 ascitic fluid Anatomy 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000006472 autoimmune response Effects 0.000 description 1
208000033354 avian tuberculosis Diseases 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
239000012267 brine Substances 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
230000001680 brushing effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910052792 caesium Inorganic materials 0.000 description 1
TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
244000309466 calf Species 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
229960000623 carbamazepine Drugs 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
210000004970 cd4 cell Anatomy 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000006727 cell loss Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
108091092259 cell-free RNA Proteins 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000003115 checkerboard titration Methods 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
238000011976 chest X-ray Methods 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
208000023819 chronic asthma Diseases 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
230000012085 chronic inflammatory response Effects 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
238000003501 co-culture Methods 0.000 description 1
238000004581 coalescence Methods 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
201000010897 colon adenocarcinoma Diseases 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
210000003022 colostrum Anatomy 0.000 description 1
235000021277 colostrum Nutrition 0.000 description 1
238000011399 combination cytotoxic chemotherapy Methods 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
231100000026 common toxicity Toxicity 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
230000002079 cooperative effect Effects 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
238000002784 cytotoxicity assay Methods 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
238000013400 design of experiment Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
235000021045 dietary change Nutrition 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
235000013325 dietary fiber Nutrition 0.000 description 1
229960002986 dinoprostone Drugs 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000009189 diving Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000001278 effect on cholesterol Effects 0.000 description 1
230000000212 effect on lymphocytes Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000008451 emotion Effects 0.000 description 1
210000003372 endocrine gland Anatomy 0.000 description 1
201000011523 endocrine gland cancer Diseases 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
201000005655 esophageal candidiasis Diseases 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
229960000285 ethambutol Drugs 0.000 description 1
238000002481 ethanol extraction Methods 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000011152 fibreglass Substances 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
229940063190 flagyl Drugs 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
230000037406 food intake Effects 0.000 description 1
210000002683 foot Anatomy 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
238000002575 gastroscopy Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
238000003205 genotyping method Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000005182 global health Effects 0.000 description 1
108010050669 glucosidase I Proteins 0.000 description 1
235000021312 gluten Nutrition 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
238000000227 grinding Methods 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
231100000226 haematotoxicity Toxicity 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
210000004247 hand Anatomy 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
208000021760 high fever Diseases 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
238000001794 hormone therapy Methods 0.000 description 1
230000009215 host defense mechanism Effects 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000036031 hyperthermia Effects 0.000 description 1
208000009326 ileitis Diseases 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000003832 immune regulation Effects 0.000 description 1
230000000899 immune system response Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000010324 immunological assay Methods 0.000 description 1
230000007233 immunological mechanism Effects 0.000 description 1
230000002584 immunomodulator Effects 0.000 description 1
230000002434 immunopotentiative effect Effects 0.000 description 1
230000000091 immunopotentiator Effects 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
229940095970 imodium Drugs 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
229940095990 inderal Drugs 0.000 description 1
230000000053 inderal effect Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
150000002484 inorganic compounds Chemical class 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000008611 intercellular interaction Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
244000000053 intestinal parasite Species 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
229960003350 isoniazid Drugs 0.000 description 1
QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
239000008274 jelly Substances 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 1
210000000867 larynx Anatomy 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000008141 laxative Substances 0.000 description 1
230000002475 laxative effect Effects 0.000 description 1
229940115286 lentinan Drugs 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
231100001022 leukopenia Toxicity 0.000 description 1
239000003446 ligand Substances 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
244000144972 livestock Species 0.000 description 1
239000000711 locust bean gum Substances 0.000 description 1
235000010420 locust bean gum Nutrition 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
239000006210 lotion Substances 0.000 description 1
208000030208 low-grade fever Diseases 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
102000036209 mannose binding proteins Human genes 0.000 description 1
108020003928 mannose binding proteins Proteins 0.000 description 1
230000035800 maturation Effects 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000005499 meniscus Effects 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
FPTPAIQTXYFGJC-UHFFFAOYSA-N metronidazole hydrochloride Chemical group Cl.CC1=NC=C([N+]([O-])=O)N1CCO FPTPAIQTXYFGJC-UHFFFAOYSA-N 0.000 description 1
238000004242 micellar liquid chromatography Methods 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
238000007431 microscopic evaluation Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
231100000324 minimal toxicity Toxicity 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
208000013465 muscle pain Diseases 0.000 description 1
210000005012 myelin Anatomy 0.000 description 1
208000001611 myxosarcoma Diseases 0.000 description 1
VGKONPUVOVVNSU-UHFFFAOYSA-N naphthalen-1-yl acetate Chemical compound C1=CC=C2C(OC(=O)C)=CC=CC2=C1 VGKONPUVOVVNSU-UHFFFAOYSA-N 0.000 description 1
230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
231100000417 nephrotoxicity Toxicity 0.000 description 1
230000007694 nephrotoxicity Effects 0.000 description 1
206010061311 nervous system neoplasm Diseases 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
230000002232 neuromuscular Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
231100001092 no hepatotoxicity Toxicity 0.000 description 1
231100000065 noncytotoxic Toxicity 0.000 description 1
230000002020 noncytotoxic effect Effects 0.000 description 1
231100000404 nontoxic agent Toxicity 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
231100000862 numbness Toxicity 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000010355 oscillation Effects 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
239000003973 paint Substances 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
238000002559 palpation Methods 0.000 description 1
208000014965 pancolitis Diseases 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000003415 peat Substances 0.000 description 1
XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
229960004448 pentamidine Drugs 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
230000002688 persistence Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
208000023974 pharynx neoplasm Diseases 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
229960002695 phenobarbital Drugs 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
229960002895 phenylbutazone Drugs 0.000 description 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
229960002036 phenytoin Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000003726 plant lectin Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
239000002574 poison Substances 0.000 description 1
101150088264 pol gene Proteins 0.000 description 1
231100000719 pollutant Toxicity 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
230000000291 postprandial effect Effects 0.000 description 1
238000012808 pre-inoculation Methods 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000004321 preservation Methods 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
210000001948 pro-b lymphocyte Anatomy 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001902 propagating effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
229960004604 propranolol hydrochloride Drugs 0.000 description 1
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
244000000040 protozoan parasite Species 0.000 description 1
230000001823 pruritic effect Effects 0.000 description 1
238000001671 psychotherapy Methods 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
238000011046 pyrogen test Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
229910052705 radium Inorganic materials 0.000 description 1
HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
238000011084 recovery Methods 0.000 description 1
201000001281 rectum adenocarcinoma Diseases 0.000 description 1
230000011514 reflex Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
239000005871 repellent Substances 0.000 description 1
230000002940 repellent Effects 0.000 description 1
230000008593 response to virus Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000003307 reticuloendothelial effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
229960001225 rifampicin Drugs 0.000 description 1
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
238000003118 sandwich ELISA Methods 0.000 description 1
230000036573 scar formation Effects 0.000 description 1
230000037390 scarring Effects 0.000 description 1
206010039722 scoliosis Diseases 0.000 description 1
230000001932 seasonal effect Effects 0.000 description 1
238000011218 seed culture Methods 0.000 description 1
230000011218 segmentation Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
208000011818 severe chest pain Diseases 0.000 description 1
238000007390 skin biopsy Methods 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
206010040872 skin infection Diseases 0.000 description 1
231100000019 skin ulcer Toxicity 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000002904 solvent Substances 0.000 description 1
235000014347 soups Nutrition 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000009295 sperm incapacitation Effects 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
210000001845 splenic macrophage Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000010959 steel Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
231100001257 subchronic oral toxicity Toxicity 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
230000037316 sun-exposed skin Effects 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
230000035900 sweating Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
229920001864 tannin Polymers 0.000 description 1
235000018553 tannin Nutrition 0.000 description 1
239000001648 tannin Substances 0.000 description 1
201000004415 tendinitis Diseases 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000036575 thermal burns Effects 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
231100000723 toxicological property Toxicity 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
230000008736 traumatic injury Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
POSZUTFLHGNLHX-KSBRXOFISA-N tris maleate Chemical compound OCC(N)(CO)CO.OCC(N)(CO)CO.OC(=O)\C=C/C(O)=O POSZUTFLHGNLHX-KSBRXOFISA-N 0.000 description 1
210000002993 trophoblast Anatomy 0.000 description 1
230000005909 tumor killing Effects 0.000 description 1
239000000439 tumor marker Substances 0.000 description 1
229950009811 ubenimex Drugs 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
229940072690 valium Drugs 0.000 description 1
210000005167 vascular cell Anatomy 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000001018 virulence Effects 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
210000002395 vitreous cell Anatomy 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000003357 wound healing promoting agent Substances 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

KR1019940701484A 1991-11-05 1991-11-05 아세만난을 포함하는 약제학적 조성물 Expired - Fee Related KR100209180B1 (ko)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US1991/008204 WO1993008810A1 (en)	1991-11-05	1991-11-05	Uses of aloe products, e.g. acemannan, in the treatment of diseases requiring intervention of the immune system for cure

Publications (1)

Publication Number	Publication Date
KR100209180B1 true KR100209180B1 (ko)	1999-07-15

Family

ID=22225937

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1019940701484A Expired - Fee Related KR100209180B1 (ko)	1991-11-05	1991-11-05	아세만난을 포함하는 약제학적 조성물

Country Status (2)

Country	Link
KR (1)	KR100209180B1 (de)
DE (1)	DE69131628T2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN112533614A (zh)	2018-03-28	2021-03-19	美国康宝莱国际公司	多糖的乙酰化

1991
- 1991-11-05 KR KR1019940701484A patent/KR100209180B1/ko not_active Expired - Fee Related
- 1991-11-05 DE DE69131628T patent/DE69131628T2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69131628T2 (de)	2000-05-31
DE69131628D1 (de)	1999-10-21

Publication	Publication Date	Title
US5441943A (en)	1995-08-15	Uses of aloe products
US5118673A (en)	1992-06-02	Uses of aloe products
EP0382840B1 (de)	1994-12-14	Aloe-zusammensetzungen und deren verwendungen
KR100605292B1 (ko)	2007-04-12	신규한 오가피 및 오가피 열매, 가시오가피 다당체, 그제조방법 및 그를 활성성분으로 함유하는 항암제 조성물
Moradali et al.	2007	Immunomodulating and anticancer agents in the realm of macromycetes fungi (macrofungi)
JPH0454124A (ja)	1992-02-21	抗ウィルス剤
Aminin	2016	Immunomodulatory properties of sea cucumber triterpene glycosides
WO1993008810A1 (en)	1993-05-13	Uses of aloe products, e.g. acemannan, in the treatment of diseases requiring intervention of the immune system for cure
CA2122604C (en)	2002-08-13	Uses of aloe products, e.g. acemannan, in the treatment of diseases requiring intervention of the immune system for cure
KR100209180B1 (ko)	1999-07-15	아세만난을 포함하는 약제학적 조성물
JPH02131428A (ja)	1990-05-21	ヒノキ科植物由来の多糖類含有活性成分の白血球障害の治療に対する使用
EP0254845A2 (de)	1988-02-03	Immun-Stimulation mit Chondroitin-sulfat
EP0965346A2 (de)	1999-12-22	Verwendung von acetylierte mannanderivate zur behandlung von chronischen atemwegserkrankungen
RU2136276C1 (ru)	1999-09-10	Средство, повышающее эффективность лечения туберкулеза
WO2000032212A1 (en)	2000-06-08	Lak activity potentiator orginating in shiitake mushroom hyphae extract and lak activity potentiating preparations containing the same
DE69133298T2 (de)	2004-04-22	Verwendung von acetylierten Mannanderivaten zur Behandlung von chronischen Atemwegserkrankungen
JPH09176022A (ja)	1997-07-08	腫瘍転移抑制剤
US4877616A (en)	1989-10-31	Process for preparing xerosin II and xerosin III, improved biological response modifiers
Gessner et al.	1992	Immunomodulatory effects of diethyldithiocarbamate
IE20030104A1 (en)	2003-08-20	A method for stimulating an immune response

Legal Events

Date	Code	Title	Description
1994-05-04	PA0105	International application	Patent event date: 19940504 Patent event code: PA01051R01D Comment text: International Patent Application
1994-09-17	PG1501	Laying open of application
1996-11-05	A201	Request for examination
1996-11-05	PA0201	Request for examination	Patent event code: PA02012R01D Patent event date: 19961105 Comment text: Request for Examination of Application
1998-10-30	E902	Notification of reason for refusal
1998-10-30	PE0902	Notice of grounds for rejection	Comment text: Notification of reason for refusal Patent event date: 19981030 Patent event code: PE09021S01D
1999-02-25	E701	Decision to grant or registration of patent right
1999-02-25	PE0701	Decision of registration	Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 19990225
1999-04-20	GRNT	Written decision to grant
1999-04-20	PR0701	Registration of establishment	Comment text: Registration of Establishment Patent event date: 19990420 Patent event code: PR07011E01D
1999-04-20	PR1002	Payment of registration fee	Payment date: 19990421 End annual number: 3 Start annual number: 1
1999-07-15	PG1601	Publication of registration
2002-04-18	PR1001	Payment of annual fee	Payment date: 20020418 Start annual number: 4 End annual number: 4
2003-04-09	PR1001	Payment of annual fee	Payment date: 20030409 Start annual number: 5 End annual number: 5
2004-03-31	PR1001	Payment of annual fee	Payment date: 20040331 Start annual number: 6 End annual number: 6
2005-04-08	PR1001	Payment of annual fee	Payment date: 20050408 Start annual number: 7 End annual number: 7
2006-04-10	PR1001	Payment of annual fee	Payment date: 20060410 Start annual number: 8 End annual number: 8
2007-04-11	PR1001	Payment of annual fee	Payment date: 20070411 Start annual number: 9 End annual number: 9
2008-04-11	FPAY	Annual fee payment	Payment date: 20080411 Year of fee payment: 10
2008-04-11	PR1001	Payment of annual fee	Payment date: 20080411 Start annual number: 10 End annual number: 10
2009-04-21	LAPS	Lapse due to unpaid annual fee
2009-04-21	PC1903	Unpaid annual fee	Termination category: Default of registration fee Termination date: 20100310